Treatment of benign prostatic hyperplasia

Details Treatment of benign prostatic hyperplasia Treatment of benign prostatic hyperplasia

2006-01-24

2006-01-24

Henley, III, Raymond J. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

Reexamination Certificate

active

06989400

ABSTRACT:
A method for treatment or prophylaxis of benign prostatic hyperplasia by administration of lonidamine or a lonidamine analog is provided. Also provided are unit dosage forms of lonidamine or an analog, useful for such treatment and prophylaxis.

REFERENCES:
patent: 3895026 (1975-07-01), Palazzo et al.
patent: 4684627 (1987-08-01), Leveen et al.
patent: 4840939 (1989-06-01), Leveen et al.
patent: 5260327 (1993-11-01), Kim et al.
patent: 5827887 (1998-10-01), Gourvest et al.
patent: 6001865 (1999-12-01), Silvestrini et al.
patent: 6319517 (2001-11-01), Cavallo et al.
patent: 6337087 (2002-01-01), Cavallo et al.
patent: 6428968 (2002-08-01), Molnar-Kimber et al.
patent: 6482802 (2002-11-01), Hu et al.
patent: 2206198 (1997-05-01), None
patent: 54256 (1989-08-01), None
patent: WO 96/40142 (1996-12-01), None
patent: WO 97/14670 (1997-04-01), None
patent: WO 98/10781 (1998-03-01), None
patent: WO 2004/064735 (2004-08-01), None
patent: WO 2004/064736 (2004-08-01), None
Isaacs et al., Prostate, Supplement, (1989), 2, 33-50 (Abstract Only, Medline Acc. No. 90148756).
Kirby, Urology, (Nov. 1, 2000), 56 (5 Suppl. 1), 3-6 (Abstract Only, Medline Acc. No. 2001035623).
Harrison's Principles of Internal Medicine, 13thed. , vol. 2, published 1994 by McGraw-Hill, Inc. (NY), pp. 18-62-1865.
Stedman's Medical Dictionary, 25thEdition, published 1990, by Williams & Wilkins, p. 65, “analog”.
Belzacq et al., Oncogene, 2001, 7579-87, 20.
Belzacq et al., Biochimie, 2002, 167-76, 84.
Berruti et al., J. Clin. Oncol., 2002, 4150-9, 20(20).
Besner et al., Oncology, 1984, 48-52, 41(supp. 1).
Besner et al., Drug Metabolism Rev., 1997, 219-234, 29(1&2).
Bunn, J. Clin. Onc., 2002, 23-33, 20(18).
Calabresi et al., Sem. Onc., 1991, 66-72, 18(2).
Cionini, Sem. Onc., 1991, 49-52, 18(2) Suppl. 4.
Comella et al., J. Clin. Onc., 1999, 1526-34, 17(5).
Corsi et al., J. Med. Chem., 1976, 778-783, 19(6).
Costello & Franklin, Oncology, 2000, 269-282, 59.
Costello et al., J. Inorg. Biochem., 2000, 161-165, 78.
Cuna et al., Apr., Sem. Onc., 1991, 18-22, 18 (2 supp. 4).
De Lena et al., Eur. J. Can., 2001, 364-8, 37.
De Lena et al., J. Clin. Onc., 1997, 3208-13, 15(10).
Floridi et al., Arch. Biochem. Biophys., 1983, 73-83, 226(1).
Floridi et al., Can. Res., Nov., 1981, 4661-6, 41.
Gatzemeier et al., Sem. Onc., 1991, 42-8, 18(2) Suppl. 4.
Grima et al., Biol. Reprod., 2001, 1500-8, 64.
Heywood et al., Chemotherapy, 1981, 91-97, 27 (Suppl. 2).
Ianniello et al., 1996, Cancer, 63-9, 78(1).
Lobl et al., Chemotherapy, 1981, 61-76, 27 (Suppl. 2).
Mansi et al., Br. J. Cancer, 1991, 593-7, 64.
Muntzing et al., J. Med. Primatol., 1975, 245-251, 4.
Orlandi et al., Int. J. Can., 1998, 377-84, 78.
Orlandi et al., Anticancer Res., 1994, 1161-4, 14.
Pacini et al., Eur. J. Cancer, 2000, 966-75, 36.
Paggi et al., Ann. NY Acad. Sci., 1988, 358-60, 551.
Portalone et al., Tumori, 1999, 239-42, 85.
Possinger et al., Sem. Onc., 1991, 58-61, 18(2) Suppl. 4.
Price et al., Cancer Chemother. Phramacol., 1996, 129-135, 38.
Privitera et al., Radiother. Onc., 1987, 285-90, 10.
Ravagnan et al., Oncogene, 1999, 2537-46, 18.
Rosso et al., Sem. Onc., 1991, 62-5, 18(2) Suppl. 4.
Rotin et al., Int. J. Radiation Oncology Biol. Phys., 1984, 1595-8, 10.
Savini et al., Breast. Can. Res. Treat., 1992, 27-34, 24.
Scarantino et al., Sem. Onc., 1991, 28-32, 18(2) Suppl. 4.
Schiffer et al., Sem. Onc., 1991, 38-41, 18(2) Suppl. 4.
Silvestrini, Sem. Onc., 1991, 2-6, 18(2) Suppl. 4.
Segre et al., Chemotherapy, 1981, 77-84, 27 (Suppl. 2).
Teicher et al., Sem. Onc., 1991, 7-10, 18(2) Suppl. 4.
Teicher et al., Eur. J. Cancer, 1994, 1411-3, 30A(10).
Vieira et al., Cell Death and Differentiation, 2000, 1146-1154, 7.
Zaniboni et al., Tumori, 1995, 435-7, 81.
Isaacs et al., “Etiology and disease process of benign prostatic hyperplasia”Prostate Suppl., 2:33-50 (1989).
Hudson et al., “Proliferative heterogeneity in the human prostate: evidence for epithelial stem cells”Lab Invest., 80:1243-1250 (2000).
Collins et al., “Benign prostatic stromal cells are regualted by basic fibroblast growth factor and transforming growth factor-beta 1”J Endocrinol., 151:315-322 (1996).
Giri et al., “Interleukin-8 is a parascrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia”Am. J Pathol., 159:139-147 (2001).
Castro et al., “Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia”Prostate, 60:153-159 (2004).
Boccardo et al., “Phase II study with Ionidamine in the treatment of hormone-refractory prostatic cancer patients”Tumori, 78:137-139 (1992).
Dudak et al., “Enhancement of radiation response of prostatic carcinoma by Ionidamine”Anticancer Res., 16:3665-3671 (1996).
Bloch et al., “Enhancement of hyperthermic toxicity by Ionidamine in the Dunning R3327G rat prostatic adenocarcinoma”Prostate, 24:131-138 (1994).
Benz et al., “Lactic dehydrogenase isozymes, 31P magnetic resonance spectroscopy, and in vitro antimitochondrial tumor toxicity with gossypol and rhodamine-123,”J Clin Invest. 79:517-523. (1987).
Eri et al., “Effects on the endocrine system of long-term treatment with the luteinizing hormone-releasing hormone agonist leuprolide in patients with benign prostatic hyperplasia”Scandinavian Journal of Clinical and Laboratory Investigation, 56: 319-325 (1996).
International Search Report and Written Opinion for PCT/US2004/001141 (WO 2004/064735) (Sep. 22, 2004).
International Search Report and Written Opinion for PCT/US2004/001146 (WO 2004/064736) (Mar. 1, 2005).
Lobl, 1979, “1-(2,4-Dicholorobenzyl)-1H-Indazole-3Carboxylic Acid (DICA), and Exfoliative Antispermatogenic Agent in the Rat”Arch Andrology2:353-63.
Shidaifat et al, 1997, “Gossypol arrests human benign prostatic hyperplastic cell growth at G0/G1 phase of the cell cycle”Anticancer Res. 17:1003-9.
Chang, 1997, “Gossypol induces spermidine/spermine N1-acetyltransferase in canine prostate epithelial cells”Biochem Biophys Res Commun. 231:383-8.

Affiliated with

Also associated with

Rating

Treatment of benign prostatic hyperplasia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of benign prostatic hyperplasia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of benign prostatic hyperplasia will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3534894